Top institutional shareholders include Kestra Advisory Services LLC (2.08%), WealthTrust Axiom LLC (1.37%), Benedetti & Gucer Inc. (0.78%), Benedetti & Gucer Inc. (0.78%), Cambridge Investment Research Advisors Inc. (0.41%) and J.W. Twitter Today, you will also get Zacks' 7 Best Stocks for the Next 30 Days. In a report issued on October 24, Guggenheim also upgraded the stock to Hold. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach. What other stocks do shareholders of Fidelity International High Dividend ETF own? Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. For the last decade, stocks have traded well above historical average P/E ratios. Axcellas pipeline includes lead therapeutic candidates in Phase 2 development for the treatment of Long COVID and NASH. Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Highlights from press releases posted on November 4, 2022. NasdaqGM - NasdaqGM Real Time Price. Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach. Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. View real-time stock prices and stock quotes for a full financial overview. Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Con.. Wedbush Adjusts Axcella Health's Price Target to $6 From $9, Citing Stock Dilution; Out.. HC Wainwright Adjusts Axcella Health's Price Target to $10 From $8, Maintains Buy Ratin.. President, Chief Executive Officer & Director, Chief Financial Officer & Senior Vice President, Chief Medical Officer & Senior Vice President. All times in Eastern Daylight Time. It can be difficult to find a deal in the stock market regardless of current market conditions. The U.S. invoked the Defense Production Act to jumpstart domestic mining and production of critical minerals such as cobalt, lithium, and rare earths, which the U.S. desperately needs for its military and green tech. The global leader in press release distribution and regulatory disclosure. Get daily stock ideas from top-performing Wall Street analysts. Details for the fireside chat are as follows. Please log in to your account or sign up in order to add this asset to your watchlist. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Highlights from press releases posted on November 4, 2022. Goldman Sachs analyst Richard Ramsden upgraded the stock from Neutral to Buy. of Operations (form 10-Q). Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. These are all manifestations of inflammation occurring in the body. Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using compositions of endogenous metabolic modulators (EMMs). All rights reserved. Initiating with an Outperform rating. The companys product candidates are comprised of EMMs and derivatives that are engineered in distinct combinations and ratios to reset multiple biological pathways, improve cellular energetics, and restore homeostasis. What A.I. NYSE to Suspend Trading Immediately in Warrants of Pine Island Acquisition Corp. (PIPP WS) and Commence Delisting Proceedings To see all exchange delays and terms of use please see Barchart's disclaimer. The global leader in press release distribution and regulatory disclosure. Top news for today. Highlights from press releases posted on November 4, 2022. NYSE to Suspend Trading Immediately in Warrants of Pine Island Acquisition Corp. (PIPP WS) and Commence Delisting Proceedings The companys unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. The global leader in press release distribution and regulatory disclosure. Get daily stock ideas from top-performing Wall Street analysts. What is Fidelity International High Dividend ETF's stock symbol? Yong covers the Technology sector, focusing on stocks such as Hims & Hers Health, GoodRx Holdings, and Accolade. In a report released on September 29, Noble Financial also reiterated a Buy rating on the stock with a $8.00 price target. Fidelity International High Dividend ETF, Receive FIDI Stock News and Ratings via Email. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $35.14 average price target, representing a 19.2% upside. 9157) that stipulates that the US dollar must be Our daily ratings and market update email newsletter. Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver What is Fidelity International High Dividend ETF's stock price today? Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Fidelity International High Dividend ETF (NYSEARCA:FIDI) pays an annual dividend of $1.01 per share and currently has a dividend yield of 6.06%. Today is October 15, 2022. which is the PreMarket Prep Stock of the Day. Initiating with an Outperform rating. Bulls Vs Bears: Mullen Automotive Short Interest Grows, Palantir Falls Into The Hands Of Value Investors, The Analysts Cant Keep Up with Arista Networks Stock, 3 Reasons Amazon Will Deliver Better 2023 Returns, A Turnaround is Brewing in Starbucks Stock, Edwards Life Sciences Stock Disaster Could Be Your Bounty, It Not All Bad News for Advanced Micro Devices Stock, After Doubling, First Solar May Keep Shining, Barrick Gold is a Hold as Long as Gold Prices Stay Stagnant, 7 Small-Cap Stocks That Could Rocket Higher in 2023, 7 Cash Rich Stocks That Offer Safety in Any Market, 7 Streaming Stocks that Will Stand up to Streaming Fatigue, 7 Agricultural Stocks to Buy to Keep Your Portfolio Well Fed, 7 Railroad Stocks to Keep Your Portfolio Chugging Along, 7 Solar Stocks Leading the Clean Energy Boom, 7 Water Stocks to Buy as the World Dries Up, 7 Sports Betting Stocks to Buy for Their Long-Term Possibilities, 7 Stocks to Buy to Outrun Rising Interest Rates, 7 Mid-Cap Stocks That Can be the Perfect Fit at Any Time. Learn about financial terms, types of investments, trading strategies, and more. For more information, please visit www.axcellatx.com. Real-time analyst ratings, insider transactions, earnings data, and more. Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts. 326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257 According to TipRanks.com, Yong is a 1-star analyst with an average return of -24.1% and a 20.0% success rate. Executive Director Perinatal HIV Research Unit, Wits Health Consortium, University of Witwatersrand; Associate Professor, Department of Paediatrics, University of Witwatersrand, South Africa; HVTN Director of International Programmes; HVTN Co-Principal Investigator; Chair of the standing committee on Health, ASSAF. CAMBRIDGE - Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 6th Annual NASH Investor 77% of retail CFD accounts lose money, Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2, Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences, Ocugen, Inc. to Present at Chardans 6th Annual Genetic Medicines Conference, Unusually active option classes on open September 28th, Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Ocugen (OCGN) and Axcella Health (AXLA), Ocugen (OCGN) Gets a Buy from Mizuho Securities, Warning! The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $35.14 average price target, representing a 19.2% upside. Copyright 2022 Surperformance. NYSE to Suspend Trading Immediately in Warrants of Pine Island Acquisition Corp. (PIPP WS) and Commence Delisting Proceedings YouTube, American Consumer News, LLC dba MarketBeat 2010-2022. Research that delivers an independent perspective, consistent methodology and actionable insight. Most recently, in August 2022, Castillo Kirsten, a Director at OCGN sold 42,000.00 shares for a total of $122,220.00. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA. Plus500. Find the latest Axcella Health Inc. (AXLA) stock quote, history, news and other vital information to help you with your stock trading and investing. Avenue Therapeutics Stock (NASDAQ: ATXI) stock price, news, charts, stock research, profile. The global leader in press release distribution and regulatory disclosure. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach. Plus, catch 5 New Zacks Strong Buy Stocks, Bull Stock of the Day, and more in the Profit from the Pros e-newsletter. GRAY, Prof Glenda MBBCH, FCP (Paeds) SA. Willey covers the Healthcare sector, focusing on stocks such as Bolt Biotherapeutics, AbCellera Biologics, and SQZ Biotechnologies. If a bee stings your hand, your hand will swell up and become stiff. The global leader in press release distribution and regulatory disclosure. By creating a free account, you agree to our, Tailor an Options Trading Strategy to Fit Your Needs. 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Identify stocks that meet your criteria using seven unique stock screeners. OCGN | Complete Ocugen Inc. stock news by MarketWatch. It can be difficult to find a deal in the stock market regardless of current market conditions. It's free, too! All times in Eastern Daylight Time. The company's shares also appear to be CAMBRIDGE - Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 6th Annual NASH Investor which is the PreMarket Prep Stock of the Day. Today, you will also get Zacks' 7 Best Stocks for the Next 30 Days. About Axcella Therapeutics (Nasdaq: AXLA). Amplitude has an analyst consensus of Moderate Buy, with a price target consensus of $19.40, a 18.3% upside from current levels. The global leader in press release distribution and regulatory disclosure. All rights reserved. Fidelity International High Dividend ETF's stock was trading at $20.5871 at the beginning of the year. This means that over the past quarter there has been an increase of insiders selling their shares of OCGN in relation to earlier this year. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach. How much money does Fidelity International High Dividend ETF make? Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Insmed (, Plus500. For the last decade, stocks have traded well above historical average P/E ratios. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocugen with a $6.33 average price target, which is a 285.98% upside from current levels. Find the latest Axcella Health Inc. (AXLA) stock quote, history, news and other vital information to help you with your stock trading and investing. View our full suite of financial calendars and market data tables, all for free. -, Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting, Chardan Lowers PT for Axcella Health to $5 From $7, Citing 'Greater Dilutionfrom Future Modeled Capital Raises', Maintains Buy Rating, AXCELLA HEALTH INC. Management's Discussion and Analysis of Financial Condition and Results Read our dividend analysis for FIDI. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Adjunct membership is for researchers employed by other institutions who collaborate with IDM Members to the extent that some of their own staff and/or postgraduate students may work within the IDM; for 3-year terms, which are renewable. Such disclosures include, but may not be limited to, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, and public conference calls and webcasts. The global leader in press release distribution and regulatory disclosure. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. There is a link between the current $1.9 billion Powerball prize money and Feder Weve updated the entire site to bring you faster navigation and increased content at every level. In a report released yesterday, Barclays also maintained a Hold rating on the stock with a $155.00 price target. How do I buy shares of Fidelity International High Dividend ETF? You will receive an email to complete the process. To request a one-on-on virtual meeting, please contact meetings@hcwco.com. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach. Avenue Therapeutics Stock (NASDAQ: ATXI) stock price, news, charts, stock research, profile. PR Newswires news distribution, Today's Top Stories. 06:07 ETThe Week in Press Releases: 10 Stories You Need to See Its pipeline of therapies includes OCU400, OCU410, OCU200, OCU100, and OCU300. One share of FIDI stock can currently be purchased for approximately $17.25. The company's unique model allows for the evaluation of its EMM compositions through non-IND clinical studies or IND clinical trials. Axcella Health : Promising Results from Phase 2a Placebo Controlled Clinical Trial f.. Axcella Health Inc. Reports Earnings Results for the Third Quarter and Nine Months Ende.. Earnings Flash (AXLA) AXCELLA THERAPEUTICS Posts Q3 Loss $-0.34, vs. Street Est of $-0 Axcella Reports Third Quarter Financial Results and Provides Business Update, Axcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022. Compare Top Brokerages Here. Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) .. Chardan Lowers PT for Axcella Health to $5 From $7, Citing 'Greater Dilutionfrom Future.. AXCELLA HEALTH INC. Management's Discussion and Analysis of Financial Condition and Re.. Transcript : Axcella Health Inc., Q3 2022 Earnings Call, Nov 01, 2022. Axcella to Present at the American Association for the Study of Liver Diseases (AASLD) .. Chardan Lowers PT for Axcella Health to $5 From $7, Citing 'Greater Dilutionfrom Future.. AXCELLA HEALTH INC. Management's Discussion and Analysis of Financial Condition and Re.. Transcript : Axcella Health Inc., Q3 2022 Earnings Call, Nov 01, 2022. Chesney covers the Healthcare sector, focusing on stocks such as Idexx Laboratories, Johnson & Johnson, and Merck & Company. We are initiating coverage of Lee Enterprises with an Outperform rating. Shares of FIDI stock can be purchased through any online brokerage account. Want to see which stocks are moving? In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX - Research Report), with a price target of $12.00. Stock Ideas and Recommendations. StockTwits Mizuho Securities analyst Uy Ear maintained a Buy rating on Ocugen (OCGN - Research Report) today and set a price target of $5.00. The webcast will be accessible in the Investors & News section on the companys website at www.axcellatx.com. The company's shares also appear to be Based on aggregate information from My MarketBeat watchlists, some companies that other Fidelity International High Dividend ETF investors own include Baidu (BIDU), Alteryx (AYX), Axcella Health (AXLA), Broadcom (AVGO), AngloGold Ashanti (AU), A10 Networks (ATEN), Asure Software (ASUR), Aflac (AFL), Archer-Daniels-Midland (ADM) and Axcelis Technologies (ACLS). Top news for today. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 6 th Annual NASH Investor Conference (3:12pm ET) This Chipotle Analyst Sees Further Upside In 2023 As The Cost Of Dining In Overtakes Dining Out. The global leader in press release distribution and regulatory disclosure. Since then, FIDI shares have decreased by 16.2% and is now trading at $17.25. The company will host a conference call at 8:30am ET that morning. Amplitude has an analyst consensus of Moderate Buy, with a price target consensus of $19.40, a 18.3% upside from current levels. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. The New Effort to Re-Anchor the US Dollar to US Gold Stock On October 7, 2022, US congressman Alex Mooney (a Republican from West Virginia) introduced a bill (the Gold Standard Restoration Act, H.R. CAMBRIDGE - Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced that management will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 6th Annual NASH Investor Conference taking place virtually on October 17th, 2022. Fidelity International High Dividend ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "FIDI.". View which stocks are hot on social media with MarketBeat's trending stocks report. CAMBRIDGE, Mass., November 01, 2022--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. Some of the key reasons for this include the company's industry leading cash flow margins, manageable debt, and comprehensive digital strategy. View real-time stock prices and stock quotes for a full financial overview. Today is October 15, 2022. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator (EMM) compositions, today announced financial results for the third quarter ended September 30, 2022 and provided a business update.This Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Fidelity International High Dividend ETF's stock is owned by a number of retail and institutional investors. See what's happening in the market right now with MarketBeat's real-time news feed. Initiating with an Outperform rating. The global leader in press release distribution and regulatory disclosure. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Is Fidelity International High Dividend ETF a good dividend stock? Dont Even Consider Buying These 7 Dead-Money Stocks, Catalyst watch: FOMC jitters, Starbucks and Pfizer earnings, Boeing and AMD events, Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and Axsome Therapeutics (AXSM), Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN), What Happened With Ocugen Shares During Wednesday's After-Hours Session, Registration on or use of this site constitutes acceptance of our. Delayed Nasdaq Get daily stock ideas from top-performing Wall Street analysts. Copyright 2022 Surperformance. The contents of our website shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. Details for the fireside chat are as follows: https://journey.ct.events/view/6b38c477-2942-428b-aed6-b4f7a0dcea88. AbbVie Announces Late-Breaking Results from Phase 2 Exploratory NOVA Trial of Novel Investigational Neurotoxin AGN-151607 for the Prevention of Postoperative Atrial Fibrillation in Cardiac Surgery AbbVie candidate for postoperative atrial fibrillation fails in mid-stage trial, Off-patent drugs make up 91% of prescriptions, but only 18% of spending - report, Better Buy: AbbVie vs. Walgreens Boots Alliance, Cancer drugs launch prices soaring, straining Medicare, report finds, Allergan Aesthetics Reaffirms Commitment to Breast Health Advocacy with Yearlong Program for Breast Cancer Awareness, Why Dividend Investors Can Still Buy AbbVie Stock With No Worries, Registration on or use of this site constitutes acceptance of our. Sign in to your free account to enjoy all that MarketBeat has to offer. When your body fights off an infection, you develop a fever. If youve already updated your profile from this new site, simply enter your email and password below. Mizuho Securities analyst Uy Ear maintained a Buy rating on Ocugen (OCGN - Research Report) today and set a price target of $5.00.The companys shares closed yesterday at $1.64. All rights reserved. An archive of the webcast replay will be available on the Companys website for up to 90 days. Axcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor Con.. Wedbush Adjusts Axcella Health's Price Target to $6 From $9, Citing Stock Dilution; Out.. HC Wainwright Adjusts Axcella Health's Price Target to $10 From $8, Maintains Buy Ratin.. President, Chief Executive Officer & Director, Chief Financial Officer & Senior Vice President, Chief Medical Officer & Senior Vice President. OCGN market cap is currently $355.2M and has a P/E ratio of -5.38. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. (C) 2022 Electronic News Publishing, source ENP Newswire. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. We believe the company is maneuvering well into a digital future. In-depth profiles and analysis for 20,000 public companies. Insmed has an analyst consensus of Strong Buy, with a price target consensus of $45.29, a 156.0% upside from current levels. Public relations and investor relations professionals rely on Business Wire for broad-based and targeted market reach. Avenue Therapeutics Stock (NASDAQ: ATXI) stock price, news, charts, stock research, profile. MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks. View the best growth stocks for 2022 here.